Early Infliximab Clearance Predicts Remission in Children with Crohn’s Disease
- 23 December 2022
- journal article
- research article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 68 (5) , 1995-2005
Abstract
Background and Aims Children with Crohn’s disease have lower response rates to infliximab, lower infliximab levels, and higher infliximab clearance on weight-based dosing than adults. We hypothesize infliximab clearance is a predictive of later outcomes on infliximab in children with Crohn’s disease. Methods In this single-center retrospective study, data were collected from charts on diagnosis, anthropometry, routine labs, infliximab therapeutic drug monitoring, infliximab dosing, disease activity, and other treatments. With these data we generated a population pharmacokinetic model using non-linear mixed effects modeling and calculated infliximab clearance for each patient over time. Patients were classified as in remission, responder-only or non-responder at 5, 10 and 16 months. Regression and ROC analyses were used to assess for early predictors of remission and response to infliximab. Results Eighty-five subjects were included, with a median follow-up of 22.3 months (IQR 10.1–36.8). Our pharmacokinetic model showed infliximab clearance was positively associated with CRP and weight, while negatively associated with albumin. In regression analyses, early infliximab clearance was the only significant, consistent predictor of remission. A 0.1 L/day increase in infliximab clearance predicted remission with an OR between 0.179 and 0.426. Differences in dosing did not account for differences in outcome. Infliximab clearance alone had moderate predictive accuracy of remission, with an AUC between 0.682 and 0.738. Conclusions Early infliximab clearance is strongly associated with remission in children with Crohn’s disease. It may be useful as a marker of response in proactive therapeutic drug monitoring to guide early dose optimization and/or changes in treatment for betterment of long-term outcomes.Keywords
Funding Information
- Women and Children's Health Research Institute
- North American Society for Pediatric Gastroenterology, Hepatology and Nutrition
This publication has 37 references indexed in Scilit:
- Concomitant Use of Immunomodulators Affects the Durability of Infliximab Therapy in Children With Crohn’s DiseaseClinical Gastroenterology and Hepatology, 2015
- Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel DiseaseGastroenterology, 2015
- Predicting Endoscopic Crohnʼs Disease Activity Before and After Induction Therapy in ChildrenInflammatory Bowel Diseases, 2015
- Antibodies to Infliximab Are Associated with Lower Infliximab Levels and Increased Likelihood of Surgery in Pediatric IBDInflammatory Bowel Diseases, 2015
- Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel DiseaseInflammatory Bowel Diseases, 2014
- Infliximab Therapy in Pediatric Patients 7 Years of Age and YoungerJournal of Pediatric Gastroenterology and Nutrition, 2014
- Proactive Therapeutic Concentration Monitoring of Infliximab May Improve Outcomes for Patients with Inflammatory Bowel DiseaseInflammatory Bowel Diseases, 2014
- Early Infliximab Trough Levels Are Associated with Persistent Remission in Pediatric Patients with Inflammatory Bowel DiseaseInflammatory Bowel Diseases, 2014
- Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trialGut, 2014
- Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical TrialsClinical Therapeutics, 2011